Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cervical Cancer
Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients
June 17th, 2009
Eli Lilly and Company announced that Phase III trial data showed the addition of Lilly's GEMZAR(R) (gemcitabine HCl for injection) to the current standard of care provided a statistically significant increase in progression-free survival at three years for women with locally advanced cervical cancer. Cervical cancer is the world's second most commonly diagnosed women's cancer, and the second most common cause of cancer death in women.(1) The current standard of care for women with locally advanced cervical cancer consists of the chemotherapy cisplatin and radiation (chemoradiation). This has been the recommended course of treatment since 1999. ...
Source: Vaccine Weekly (2009-06-17)
|
